|
 |
|
|
|
|
|
| |
 |
|
Founder
and Managing Partner |
|
|
|
|
| |
|
|
|
|
| |
Professor Abshagen is the founder of HI (1996) and has concentrated
the last years on building HI to become a leading European venture
firm. He brings to the firm a 20 years track record in building
global pharmaceutical businesses. Professor Abshagen is a board
certified internist and clinical pharmacologist and was instrumental
in establishing clinical pharmacology as an academic and medical
discipline in Germany.
He served as President & CEO with worldwide responsibility for
the pharmaceutical business of Boehringer Mannheim (now Roche)
and built its U.S. pharma business from scratch to a break-up
value > $ 1bn. Already in the early 80ies he integrated molecular
biology and genetic engineering into drug discovery and development.
During his tenure, 10 novel drugs including 3 biologics were
discovered, developed and launched into world markets. Among
those therapeutics were 3 blockbusters (Carvedilol - >$ 2bn,
Umsatz, EPO - $ 2bn, Ibandronat - $ 1bn).
Prof Abshagen currently holds supervisory board seats in Arthro
Kinetics, Digilab and invendo medical
and is honorary senator of the University of Heidelberg.
|
|
|
|
| |
|
|
|
|
| |
back
to the overview |
|
|
|
|
|
|
|
|
|
